Incorporation of Prognostic and Predictive Factors Into Glioma Clinical Trials
- 322 Downloads
Treatment of brain tumors is increasingly informed by biomarkers that predict patient prognosis and response to therapy. While this progress represents a great opportunity for the field of neuro-oncology, it also presents significant challenges. Biomarkers are not straightforward to identify, and previously used clinical trial paradigms are poorly suited to the task of identifying treatments effective only in selected subsets of patients. Unless investigators adapt new tools and procedures that better account for the biological diversity of gliomas, future clinical trials run the dual risk of missing important treatment effects and exposing patients to interventions destined to prove ineffective for their tumors. In this article, we will review the progress made in the past decade with respect to biomarkers in neuro-oncology, address barriers to ongoing progress, and discuss clinical trial designs that may prove useful in moving neuro-oncology fully into the era of personalized medicine.
KeywordsBrain tumor Glioma Glioblastoma Clinical trial Biomarker Prognostic Predictive
No potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 10.• Wick W, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13:707–15. Multicenter randomized trial demonstrating that MGMT methylation is predictive of treatment response in elderly patients with glioblastoma.PubMedCrossRefGoogle Scholar
- 13.van den Bent MJ, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715–22.PubMedCrossRefGoogle Scholar
- 14.Cairncross G, et al. Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: long-term results of the RTOG 9402 phase III study. J Clin Oncol. 2012;30(suppl; abstr 2008b).Google Scholar
- 15.Van den Bent MJ, et al. Long-term follow-up results of EORTC 26951: a randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD). J Clin Oncol. 2012;30(suppl; abstr 2).Google Scholar
- 16.Clinicaltrials.gov. Phase III intergroup study of radiotherapy versus temozolomide alone versus radiotherapy with concomitant and adjuvant temozolomide for patients with 1p/ 19q codeleted anaplastic glioma. Available at: http://clinicaltrials.gov/ct2/show/NCT00887146. Accessed on September 1, 2012.
- 17.Clinicaltrials.gov. Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup Trial. Available at: http://clinicaltrials.gov/ct2/show/NCT00626990. Accessed on September 1, 2012.
- 28.Myung JK, et al. IDH1 mutation of gliomas with long-term survival analysis. Oncol Rep. 2012;28(5):1639–44.Google Scholar
- 30.Shibahara I, et al. IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol. 2011.Google Scholar
- 37.Aldape K, et al. RTOG 0525: molecular correlates from a randomized phase III trial of newly diagnosed glioblastoma. J Clin Oncol. 2011;29:(suppl; abstr LBA2000).Google Scholar
- 38.Quillien V, et al. Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer. 2012;118:4201–11.PubMedCrossRefGoogle Scholar
- 56.Available at: http://clinicaltrials.gov/ct2/show/NCT01266031. Accessed on October 14, 2012.
- 58.• Galanis E, et al. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012;13:e196–204. Response Assessment in Neuro-Oncology (RANO) group position paper regarding future phase II trial designs, including importance of biomarker evaluation.PubMedCrossRefGoogle Scholar